Financial Performance Highlights (FY 2025-26 vs FY 2024-25)
- Total Income: ₹212.31 crore (PY: ₹153.63 crore) - 38.2% increase
- Total Expenses: ₹194.25 crore (PY: ₹140.13 crore) - 38.6% increase
- Profit Before Tax: ₹18.06 crore (PY: ₹13.50 crore) - 33.8% increase
- Provision for Tax: ₹4.94 crore (PY: ₹3.41 crore) - 44.9% increase
- Profit After Tax: ₹13.12 crore (PY: ₹10.09 crore) - 30.0% increase
- Turnover: ₹206.37 crore (PY: ₹150.94 crore) - 36.7% increase
AGM Details
- Date: Tuesday, 22nd September 2026
- Time: 4:00 PM
- Mode: Video Conferencing/Other Audio Visual Means
- Record Date: Friday, 21st August 2026
- Book Closure: 16th September 2026 to 22nd September 2026 (both days inclusive)
Ordinary Business
1. Adoption of Financial Statements: To consider and adopt audited financial statements for FY ended 31st March 2026 with reports of Board of Directors and Auditors
2. Appointment of Director: To appoint Haresh Kapurlal Mehta (DIN: 01080289) who retires by rotation and offers himself for re-appointment
Special Business
3. Re-appointment of Rishit Mehta: As Whole-Time Director for 3 years from 18th September 2026 to 18th September 2029 with monthly remuneration not exceeding ₹7.5 lakh plus benefits
4. Re-appointment of Haresh Mehta: As Chairman & Whole-Time Director for 3 years from 18th September 2026 to 18th September 2029 with monthly remuneration not exceeding ₹7.5 lakh plus benefits
5. Increase in Remuneration for Harshit Mehta: Managing Director's remuneration increased to not exceeding ₹7.5 lakh per month effective 1st October 2026 for remaining tenure up to 17th September 2028
6. Increase in Professional Fees for Priyal Rishit Mehta: Professional consultant fees increased to ₹5 lakh per month effective 1st October 2026 (Related Party transaction)
7. Increase in Remuneration for Shweta Harshit Mehta: Regulatory Deputy Manager's remuneration increased to ₹5 lakh per month effective 1st October 2026 (Related Party transaction)
Dividend
No dividend recommended for FY 2025-26.
Corporate Actions
No changes in share capital during FY 2025-26. No issuance or buyback of securities, sweat equity, or stock options.
Capital Structure
- Authorized Share Capital: ₹17.00 crore (8.5 crore equity shares of ₹2 each)
- Issued, Subscribed and Paid-up: ₹16.60 crore (8.2984 crore equity shares of ₹2 each)
- Promoter Holding: Key promoters include Haresh Mehta (20.22%), Rishit Mehta (12.65%), Harshit Mehta (10.39%), Rita Mehta (8.05%)
Key Managerial Personnel Changes
- Mr. Hasan Bohra resigned as Company Secretary & Compliance Officer effective 8th August 2025
- Ms. Vidhi Shah appointed as Company Secretary & Compliance Officer effective 18th February 2026
- Mr. Maheshkumar Darji appointed as Executive Director effective 30th July 2025 for 3 years
Board Composition
As of 31st March 2026:
- Mr. Haresh Mehta (Chairman & Whole-Time Director)
- Mr. Harshit Mehta (Managing Director)
- Mr. Rishit Mehta (Whole-Time Director)
- Ms. Rita Mehta (Non-Executive Director)
- Mr. Deepak Vekaria (Independent Director)
- Mr. Bharat Rathod (Independent Director)
- Mr. Maheshkumar Darji (Executive Director)
- Mr. Deepesh Shah (Independent Director)
- Mr. Kunal Vora (Independent Director)
- Mr. Anuj Mody (Independent Director)
Compliance Issues Noted
1. Delayed Filing: e-Form MR-1 filed belatedly on 26th February 2026 after payment of additional fees
2. Compliance Officer Gap: No Compliance Officer from 9th August 2025 to 17th February 2026 (6 months, 9 days)
3. Stock Exchange Fines: Paid ₹63,720 + GST each to BSE and NSE for compliance officer vacancy
Credit Ratings
- Long Term Bank Facilities: Crisil BBB-/Stable
- Short Term Bank Facilities: Crisil A3
CSR Activities
- Average Net Profit (last 3 years): ₹11.87 crore
- CSR Obligation (2%): ₹23.75 lakh
- Amount Available for Set-off: ₹7.49 lakh
- Net CSR Obligation: ₹16.26 lakh
- Actual CSR Spent: ₹27.00 lakh (excess of ₹10.74 lakh)
- Projects Supported: Education for backward classes through Kapurlal Tribhuvandas Charitable Trust (₹17 lakh for Babaji Jadhav Smarak School, ₹10 lakh for Ashram School)
Key Ratios (FY 2025-26 vs FY 2024-25)
- Current Ratio: 1.66 (1.70)
- Debt-Equity Ratio: 0.25 (0.22)
- Inventory Turnover: 5.85 (5.53)
- Trade Receivables Turnover: 2.97 (2.83)
- Return on Net Worth: 20% (18%)
- Net Profit Margin: 6% (7%)
Foreign Exchange
- Earnings: ₹179.01 crore (FOB)
- Outgo: ₹2.59 crore for purchases + ₹0.96 crore for expenses
Employee Strength
105 permanent employees as on 31st March 2026
Legal Proceedings
No significant material orders passed by regulators or courts impacting going concern status. No proceedings under Insolvency and Bankruptcy Code, 2016.
Voting Arrangements
- Remote e-Voting Period: 19th September 2026 (9:00 AM) to 21st September 2026 (5:00 PM) through NSDL
- Scrutinizer: Ms. Shreya Shah, Practicing Company Secretary
Plant Location
Plot no. 7, 8 & 9, Dewan & Sons, Udyog Nagar, Lokmanya Nagar, Palghar West - 401404
#Tags: #MedicoRemedies #AnnualReport #SEBIDisclosure #AGM2026 #Pharma #FinancialResults